Kestra Medical Technologies, Ltd.(KMTS)Earnings, Financials & Key RatiosKestra Medical Technologies, Ltd. (KMTS) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q3
while the $291.3M cash position provides a significant runway, the company's inability to convert revenue into positive operating cash flow, evidenced by a 0.54 OCF/NI ratio, warrants caution until unit economics improve.
Kestra Medical Technologies, Ltd. (KMTS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Kestra Medical Technologies, Ltd. (KMTS) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 17, 2026 | $0.61vs $0.60-1.7% | $25Mvs $23M+7.3% |
| Q4 2025 | Dec 11, 2025 | $0.62vs $0.59-4.4% | $23Mvs $23M-1.3% |
| Q4 2025 | Sep 11, 2025 | $0.46vs $0.66+30.3% | $19Mvs $21M-6.5% |
| Q3 2025 | Jul 17, 2025 | $1.05 | $17M |
Recent stock market news and headlines for Kestra Medical Technologies, Ltd. (KMTS)
KIRKLAND, Wash., June 30, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, is scheduled to report fourth quarter fiscal 2026 financial results after the market closes on Tuesday, July 14.
This cardiac device innovator saw a notable insider sale, as routine portfolio moves continue amid its push in digital health solutions.
Key metrics vs top competitors for Kestra Medical Technologies, Ltd. (KMTS)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $27.85 | $1.63B | -5.43 | 115.05% | -190.28% | -55.41% | 0.12% | |
| $83.83 | $107.63B | 22.47 | 8.43% | 13.2% | 9.78% | — | |
| $95.84 | $166.94B | 25.76 | 5.67% | 13.91% | 12.09% | — | |
| $45.30 | $67.33B | 23.35 | 19.87% | 17.23% | 14.67% | — | |
| $94.82 | $54.6B | 51.81 | 11.55% | 17.34% | 10.54% | — | |
| $83.58 | $4.59B | -18.78 | 10.74% | 7.47% | 9.13% | — |
Kestra Medical Technologies, Ltd. (KMTS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Kestra Medical Technologies, Ltd. (KMTS) SEC filings — annual & quarterly reports (10-K, 10-Q)
Mar 17, 2026·SEC
Dec 11, 2025·SEC
Dec 4, 2025·SEC
Jul 17, 2025·SEC
Get notified when KMTS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Kestra Medical Technologies, Ltd. (KMTS) stock FAQ — growth, dividends, profitability & financials explained
Kestra Medical Technologies, Ltd. (KMTS) reported $83.7M in revenue for fiscal year 2025.
Kestra Medical Technologies, Ltd. (KMTS) grew revenue by 115.1% over the past year. This is strong growth.
Kestra Medical Technologies, Ltd. (KMTS) reported a net loss of $144.8M for fiscal year 2025.
Yes, Kestra Medical Technologies, Ltd. (KMTS) pays a dividend with a yield of 0.12%. This makes it attractive for income-focused investors.
Kestra Medical Technologies, Ltd. (KMTS) has a return on equity (ROE) of -55.4%. Negative ROE indicates the company is unprofitable.
Kestra Medical Technologies, Ltd. (KMTS) had negative free cash flow of $120.0M in fiscal year 2025, likely due to heavy capital investments.
